EP1895861A1 - A combination of seal oil and cold-pressed virgin olive oil - Google Patents
A combination of seal oil and cold-pressed virgin olive oilInfo
- Publication number
- EP1895861A1 EP1895861A1 EP05750010A EP05750010A EP1895861A1 EP 1895861 A1 EP1895861 A1 EP 1895861A1 EP 05750010 A EP05750010 A EP 05750010A EP 05750010 A EP05750010 A EP 05750010A EP 1895861 A1 EP1895861 A1 EP 1895861A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oil
- combination
- monocytes
- virgin olive
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003921 oil Substances 0.000 title claims abstract description 30
- 235000019198 oils Nutrition 0.000 title claims abstract description 30
- 239000010463 virgin olive oil Substances 0.000 title claims abstract description 8
- 239000013589 supplement Substances 0.000 claims abstract description 8
- 235000005911 diet Nutrition 0.000 claims abstract description 6
- 230000037213 diet Effects 0.000 claims abstract description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 12
- 230000000770 proinflammatory effect Effects 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000002528 coronary thrombosis Diseases 0.000 claims description 2
- 239000008157 edible vegetable oil Substances 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 210000001616 monocyte Anatomy 0.000 description 24
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 16
- 229940012843 omega-3 fatty acid Drugs 0.000 description 16
- 239000006014 omega-3 oil Substances 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000012716 cod liver oil Nutrition 0.000 description 11
- 239000003026 cod liver oil Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 102000002262 Thromboplastin Human genes 0.000 description 9
- 108010000499 Thromboplastin Proteins 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 235000014107 unsaturated dietary fats Nutrition 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000007670 refining Methods 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 230000036523 atherogenesis Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102000000018 Chemokine CCL2 Human genes 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000283153 Cetacea Species 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004139 eicosanoid metabolism Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010935 polish filtration Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/003—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2131—Olive
Definitions
- the present invention relates to a combination of oils as a supplement to, or component of, a regular diet to counteract the development of coronary heart disease (CHD), thrombosis and other inflammatory diseases such as psoriasis and rheumatism.
- the combination according to the invention comprises seal oil and virgin olive oil.
- Atherosclerotic lesions are formed when three cellular components of the circulation, monocytes, platelets and T-lymphocytes, react with LDL-cholesterol and two cell types in the artery wall, endothelial cells (EC) and the smooth muscle cells (SMC).
- the precursor of atherogenesis is the recruitment of monocytes and lymphocytes from the peripheral blood to the intima of the vessel wall, an event that appears to depend upon the local presence of large amounts of LDL.
- LDL vascular cell adhesion molecule- 1
- IAM-I intracellular adhesion molecule-1
- LDL oxidised, glycosylated etc.
- Modified forms of LDL are of particular interest since the modification of LDL is associated with inflammatory reactions triggered by processes that are initiated due to the adhesion and transmigration of monocytes and lymphocytes into the intima.
- monocytes play a central role in the early phase of atherogenesis.
- One of the first events in the atherosclerotic process is the mobilisation of monocytes into the intima. Since the recruitment of monocytes and their penetration through the endothelium are associated with the secretion of activation products such as cytokines and growth factors, it may be assumed that the functional reactivity of the circulating monocytes is very important. It is suggested that chronic infectious diseases may affect the functional reactivity by activating the monocytes and making them more liable to produce and release harmful products such as cytokines and chemokines in response to stress.
- the inventor has, inter alia, investigated in vitro how LPS-induced reactivity in monocytes in whole blood relates to the lipid profile in the serum of healthy individuals with a history of myocardial infarction (MI) or cancer in their close family.
- MI myocardial infarction
- 20 had moderately high cholesterol (7.1 -10.2 mmol/1), whilst 34 had normal cholesterol.
- 19 had hyperactive monocytes (high responders), whilst 15 had normally responding monocytes.
- LPS-induced thromboplastin (TF), TNFa and IL-6 were on average 3-4 times higher in the group with normal cholesterol compared with the group with moderately high cholesterol.
- statins may be more important than their cholesterol- reducing effect (Balk et al. "Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review" Ann Intern Med. 2003; 139:670-82. Review).
- the dietary oil according to the invention contains omega-3 fatty acids. These are known to reduce the risk of arrhythmia which can lead to sudden death. Omega-3 fatty acids are also known to reduce the risk of thrombosis which can lead to heart attack and stroke. They reduce the growth rate of atherosclerotic plaque, and thus have antiinflammatory properties as lesion formation in the atherogenic process is mediated by proinflammatory reactions. Furthermore, omega-3 fatty acids improve endothelial function, reduce the level of triglycerides in the blood and lower the blood pressure slightly (for a brief overview, reference is made to PM Kris-Etherton, WS Harris, LJ Appell “Arterioscler Thromb Vase Biol.” 2003; 23: 151-2).
- omega-3 fatty acids hi view of the properties of omega-3 fatty acids, it would be expected that a supplement of omega-3 fatty acids ought to be sufficient to prevent cardiovascular disease.
- clinical studies carried out in Norway have shown negative effects of omega- 3 fatty acids (I Seljefot, O Johansen, H Arnesen, JB Eggesbo, AB Westvil, P JX ⁇ erulf, "Thromb Haemost.” 1999; 81:566-70; O Johansen, I Seljefot, AT Hostmark, H Arnesen “Arterioscler Thromb Vase Biol.” 1999; 19; 1681-6).
- Nutritional quality is also affected by the quantitative content of biologically active molecules. These nutrients are affected by several factors such as environment, availability, chemical stability, the degree of processing and the form in which the nutrition is delivered.
- Fish oils are extracted from whole fish, fish liver (primarily cod liver) or by-products (primarily salmon). Oils from marine mammals are produced from blubber and external adipose tissue.
- Marine oils have a high content of unsaturated fatty acids.
- the use of high temperatures during the extraction process will cause undesirable effects such as the initiation of oxidation reactions, the destruction of antioxidants and the formation of molecules that give the oil an odour and taste. Detectable changes occur in lipid components during heat extraction at temperatures of more than 4O 0 C, compared with their "virgin" state in the cells.
- the conventional refining process consists of four main steps: polishing, acid washing, bleaching and deodorisation. In addition, steps such as clarification (filtration, sedimentation), mixing of different batches, winterisation and polishing filtration are also used. During the refining steps, a number of chemical reactions (hydrolysis, autooxidation, isomerisation, conjugation, polymerisation, pyrolysis and dehydration) will occur independent of the process conditions.
- the refining process must allow for the removal of any undesirable by-products that might be formed.
- the number of treatment steps is also influenced by the quality of the crude oil, including accompanying substances, amount and type of impurities, former oxidative and hydrolytic damage. Quality criteria for the dietary oil, environmental conditions, finances and a reduction in loss of material are all critical criteria when selecting the refining process.
- Refining marine oils to improve their sensory properties and stability may also destroy potent antioxidants and components having potentially beneficial functional properties.
- Polyunsaturated fatty acids including omega-3 fatty acids, may be incorporated into LDL particles and render them more prone to oxidation.
- oxidation of LDL particles is one of the main reactions in the early phase of atherogenesis, prevention of oxidation will prevent the formation of foam cells in intima (for an overview, reference is made to B ⁇ sterud, E Bj ⁇ rklid, "Physiological Reviews", 2003, 83: 1069-112. Review).
- antioxidants have been shown to reduce lesion formation in animal models (M. Aviram, B. Fuhrman "Ann N Y Acad ScL" 2002; 957: 146-61. Review).
- antioxidants are also important in the down-regulation of eicosanoid metabolism.
- the lipoxygenase pathway which leads to the formation of, inter alia, leucotrien B4, is inhibited by antioxidants with a subsequent reduction in LTB4 production.
- inhibition of the LTB4 receptor in transgenic mice which were predisposed to atherosclerosis reduced lesion formation by about 70% (RJ Aiello, PA Bourassa, S Lindsey, W Weng, A. Freeman, HJ Showell, "Aterioscler Thromb Vase Biol.” 2002; 22: 443-9).
- a subject (the inventor) who has used the dietary oil according to the invention for a period of ten years has very low LTB4 generation in LPS-induced whole blood.
- the addition of commercial LTB4 to the subject's blood causes the LPS-induced TF (Tissue Factor) to rise by more than 70% and the blood response to LPS is once again among the highest measured ( ⁇ sterud, unpublished data).
- LPS-induced TF Tissue Factor
- the combination of oils according to the invention combines the effect of omega-3 fatty acids and a synergistic component which gives an antioxidation effect both in vivo and in vitro.
- This combination has, according to the invention, given surprising advantageous properties in the form very good clinical effects, better functional properties and longer storage life.
- the inventors have shown that a particularly advantageous effect is obtained using a product that contains oil from marine mammals, preferably the seal, and cold-pressed virgin olive oil, both of these components being produced in a per se known way. The effect obtained may seem to be more pronounced than would be expected if each component were used alone.
- the invention relates to a combination of oils as a supplement to a regular diet, characterised in that it comprises a combination of seal oil and cold-pressed virgin olive oil.
- the invention also relates to the use of the combination according to the invention as a component in an oil-in-water or water-in-oil emulsion in foodstuffs.
- the invention relates to the use of the combination according to the invention, optionally together with adjuvants, for example, for preparing a composition for counteracting the development of coronary heart disease and thromboses and to suppress psoriasis, rheumatism and other proinflammatory diseases.
- Table 1 shows a change in some of the most important parameters related to coronary heart disease (CHD).
- HDL-chol is the beneficial cholesterol and any positive change in this is a good thing.
- Hypersensitive C-reactive protein (hs-CRP) reflects chronic inflammatory reactions in the body. It has been shown that increased values of between 0 and 5 mmol/1 are a good risk indicator for coronary heart disease, and especially when the proportion of total cholesterol over HDL cholesterol related to hs-CRP increases (Rifai N, Ridker PM "Inflammatory markers and coronary heart disease” Curr Opin Lipidol. 2002; 13: 383-9. Review).
- Monocyte chemotactic protein-1 (MCP-I) is a very important chemoattractant protein which plays a major role in the development of atherosclerosis in that it mobilises proinflammatory substances at the site of their production. Thus, any dietary supplement which gives a reduction in MCP-I may be highly beneficial.
- LTB4 and TxB2 (a stable product of TxA2) are proinflammatory products derived from the metabolism of arachidonic acid.
- the above study was carried out on respectively 23, 18 and 19 healthy people in the control group, CLO and the group that received the dietary oil of the invention.
- the fatty acid composition before and after was determined in serum samples.
- the combination of oils according to the invention has the potential to increase the beneficial HDL cholesterol, significantly reduce the important marker and the risk factor for coronary heart disease (hs-CRP) and further reduce MCP-I more efficiently than CLO.
- the beneficial effect of reducing the proinflammatory products TxA2 and LTB4 is at the same level as for CLO.
- the dietary oil according to the invention as a dietary supplement has significantly more anti-inflammatory effects than CLO, and is superior to olive oil, which has also been used alone as a control in several studies of omega-3 fatty acids and fish oils.
- the effect of the edible oil according to the invention probably occurs through a synergistic combination of omega-3 fatty acids from the marine oil and strong antioxidants present in the virgin olive oil.
Abstract
A combination of oils as a supplement to, or component of, a regular diet, wherein it comprises marine oil, preferably seal oil, and cold-pressed virgin olive oil.
Description
Combination of oils
The present invention relates to a combination of oils as a supplement to, or component of, a regular diet to counteract the development of coronary heart disease (CHD), thrombosis and other inflammatory diseases such as psoriasis and rheumatism. The combination according to the invention comprises seal oil and virgin olive oil.
Atherosclerotic lesions are formed when three cellular components of the circulation, monocytes, platelets and T-lymphocytes, react with LDL-cholesterol and two cell types in the artery wall, endothelial cells (EC) and the smooth muscle cells (SMC).
The precursor of atherogenesis is the recruitment of monocytes and lymphocytes from the peripheral blood to the intima of the vessel wall, an event that appears to depend upon the local presence of large amounts of LDL. As LDL accumulates, bound lipid and protein are oxidised and glycosylated. Cells in the vessel wall seem to interpret this change as a danger signal and call for reinforcements from the body's defence system. These processes appear to promote an up-regulation of adhesion molecules on the endothelial cells, particularly vascular cell adhesion molecule- 1 (VCAM-I) and intracellular adhesion molecule-1 (ICAM-I). Thus, monocyte and lymphocyte recruitment is initiated. This leads to increased transmigration of monocytes, up- regulated exposure of adhesion molecules on the endothelium, and the production and release of chemoattractants. These are essential events for the transfer of monocytes to the intima, and the concurrent differentiation of monocytes into macrophages. Available modified LDL is also a prerequisite for the further development of macrophages into foam cells (fatty macrophages), which is the main cause of the formation of fatty streaks under the endothelium of the vessel wall. Modified forms of LDL (oxidised, glycosylated etc.) are of particular interest since the modification of LDL is associated with inflammatory reactions triggered by processes that are initiated due to the adhesion and transmigration of monocytes and lymphocytes into the intima.
As mentioned above, it is well known that monocytes play a central role in the early phase of atherogenesis. One of the first events in the atherosclerotic process is the mobilisation of monocytes into the intima. Since the recruitment of monocytes and their penetration through the endothelium are associated with the secretion of activation products such as cytokines and growth factors, it may be assumed that the functional reactivity of the circulating monocytes is very important. It is suggested that chronic infectious diseases may affect the functional reactivity by activating the monocytes and
making them more liable to produce and release harmful products such as cytokines and chemokines in response to stress.
To date, little is known as to exactly how the functional properties of circulating monocytes relate to atherogenesis. However, it is well established that hyperactive monocytes play a crucial role in the pathophysiology of rheumatism, psoriasis and other inflammatory diseases. We also know that atherogenesis is a proinflammatory disease. It may therefore be assumed that the proinflammatory function of circulating monocytes may be associated with increased risk of coronary heart disease (CHD), and that high cholesterol levels may augment production of proinflammatory products such as oxygen radicals, cytokines etc.
For many years, the inventor has observed that the reactivity of monocytes, as monitored by the production of thromboplastin (Tissue Factor = TF) and cytokines such as TNFa and IL-6 in lipopolysaccharide (LPS) stimulated blood, varies between individuals from low activity to very high activity (high responders). This property of monocytes seems to be hereditary (østerud et al, "Blood Coagulation and Fibrinolysis" 2002; 13:399-405). The inventor has, inter alia, investigated in vitro how LPS-induced reactivity in monocytes in whole blood relates to the lipid profile in the serum of healthy individuals with a history of myocardial infarction (MI) or cancer in their close family. Of a total of 54 individuals in the myocardial infarction (MI) families, 20 had moderately high cholesterol (7.1 -10.2 mmol/1), whilst 34 had normal cholesterol. Of the individuals with normal cholesterol, 19 had hyperactive monocytes (high responders), whilst 15 had normally responding monocytes. LPS-induced thromboplastin (TF), TNFa and IL-6 were on average 3-4 times higher in the group with normal cholesterol compared with the group with moderately high cholesterol. Thus, no positive correlation between hyperactive monocytes and cholesterol level was found. All 42 individuals in the families with a history of cancer had normal cholesterol, and LPS-induced thromboplastin (TF), TNFa and IL-6 were not significantly different from the values of the group with moderately high cholesterol among the myocardial infarction (MI) families. This supports the conclusion that moderately high cholesterol is not associated with increased monocyte activation in whole blood, whilst hyperactive peripheral blood monocytes are a significant risk factor for the development of coronary heart disease.
It is probably at least as important to reduce the reactivity of monocytes, and thus the production of proinflammatory products such as cytokines, oxidative metabolites and
growth factors, as it is to reduce the cholesterol level. New studies also show that the anti-inflammatory effect of statins may be more important than their cholesterol- reducing effect (Balk et al. "Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review" Ann Intern Med. 2003; 139:670-82. Review).
The dietary oil according to the invention contains omega-3 fatty acids. These are known to reduce the risk of arrhythmia which can lead to sudden death. Omega-3 fatty acids are also known to reduce the risk of thrombosis which can lead to heart attack and stroke. They reduce the growth rate of atherosclerotic plaque, and thus have antiinflammatory properties as lesion formation in the atherogenic process is mediated by proinflammatory reactions. Furthermore, omega-3 fatty acids improve endothelial function, reduce the level of triglycerides in the blood and lower the blood pressure slightly (for a brief overview, reference is made to PM Kris-Etherton, WS Harris, LJ Appell "Arterioscler Thromb Vase Biol." 2003; 23: 151-2).
hi view of the properties of omega-3 fatty acids, it would be expected that a supplement of omega-3 fatty acids ought to be sufficient to prevent cardiovascular disease. However, clinical studies carried out in Norway have shown negative effects of omega- 3 fatty acids (I Seljefot, O Johansen, H Arnesen, JB Eggesbo, AB Westvil, P JXαerulf, "Thromb Haemost." 1999; 81:566-70; O Johansen, I Seljefot, AT Hostmark, H Arnesen "Arterioscler Thromb Vase Biol." 1999; 19; 1681-6). Patients with cardiovascular disease who were given a supplement of omega-3 fatty acids for six months experienced a doubling of both angina and occlusions compared with controls. An increase in cytokine production was also observed, which is indicative of an increase in proinflammatory peroxidation of polyunsaturated fatty acids in vivo (for an overview, reference is made to H. Arnesen, "Lipids" 2001; 36 Suppl: S 103-6).
The findings referred to above are in accordance with the inventor's own results with respect to diets including a supplement of omega-3 fatty acids. Thus, the antiinflammatory effect of supplementing the diet of healthy individuals with an omega-3 fatty acid concentrate was not significant compared with a corresponding amount of omega-3 fatty acids in the form of cod-liver oil (CLO). The combination of oils according to the invention, on the other hand, gave a significant reduction in LPS- induced cytokine and eicosanoid production after the ingestion of 15 ml of oil per day for 10 weeks.
The object of modern refining processes for producing oil from fish and marine mammals is to make the oil healthier, safer, more palatable and more storage-stable. The removal of molecules that give an undesirable taste or odour in order to enhance the sensory properties may, however, destroy potent antioxidants. Nutritional quality is also affected by the quantitative content of biologically active molecules. These nutrients are affected by several factors such as environment, availability, chemical stability, the degree of processing and the form in which the nutrition is delivered. Fish oils are extracted from whole fish, fish liver (primarily cod liver) or by-products (primarily salmon). Oils from marine mammals are produced from blubber and external adipose tissue.
The processing of marine oils to render them suitable for human consumption can be problematic. Traditional extraction techniques involve heating or steam-stripping the raw material in order to release the lipids. Marine oils have a high content of unsaturated fatty acids. The use of high temperatures during the extraction process will cause undesirable effects such as the initiation of oxidation reactions, the destruction of antioxidants and the formation of molecules that give the oil an odour and taste. Detectable changes occur in lipid components during heat extraction at temperatures of more than 4O0C, compared with their "virgin" state in the cells. To obtain a stable, sensorily acceptable and safe product, the removal of a number of components (proteins, peptides, amino acids, free fatty acids, phospholipids, pigments, sterols, transformation products, metals, and possible toxic substances) is usually necessary. The conventional refining process consists of four main steps: polishing, acid washing, bleaching and deodorisation. In addition, steps such as clarification (filtration, sedimentation), mixing of different batches, winterisation and polishing filtration are also used. During the refining steps, a number of chemical reactions (hydrolysis, autooxidation, isomerisation, conjugation, polymerisation, pyrolysis and dehydration) will occur independent of the process conditions. The refining process must allow for the removal of any undesirable by-products that might be formed. The number of treatment steps is also influenced by the quality of the crude oil, including accompanying substances, amount and type of impurities, former oxidative and hydrolytic damage. Quality criteria for the dietary oil, environmental conditions, finances and a reduction in loss of material are all critical criteria when selecting the refining process.
Refining marine oils to improve their sensory properties and stability may also destroy potent antioxidants and components having potentially beneficial functional properties.
Polyunsaturated fatty acids, including omega-3 fatty acids, may be incorporated into LDL particles and render them more prone to oxidation. As oxidation of LDL particles is one of the main reactions in the early phase of atherogenesis, prevention of oxidation will prevent the formation of foam cells in intima (for an overview, reference is made to B østerud, E Bjørklid, "Physiological Reviews", 2003, 83: 1069-112. Review). Thus, antioxidants have been shown to reduce lesion formation in animal models (M. Aviram, B. Fuhrman "Ann N Y Acad ScL" 2002; 957: 146-61. Review). Furthermore, antioxidants are also important in the down-regulation of eicosanoid metabolism. The lipoxygenase pathway, which leads to the formation of, inter alia, leucotrien B4, is inhibited by antioxidants with a subsequent reduction in LTB4 production. Recently, it has been shown, inter alia, that inhibition of the LTB4 receptor in transgenic mice which were predisposed to atherosclerosis reduced lesion formation by about 70% (RJ Aiello, PA Bourassa, S Lindsey, W Weng, A. Freeman, HJ Showell, "Aterioscler Thromb Vase Biol." 2002; 22: 443-9).
A subject (the inventor) who has used the dietary oil according to the invention for a period of ten years has very low LTB4 generation in LPS-induced whole blood. The addition of commercial LTB4 to the subject's blood causes the LPS-induced TF (Tissue Factor) to rise by more than 70% and the blood response to LPS is once again among the highest measured (østerud, unpublished data).
The combination of oils according to the invention combines the effect of omega-3 fatty acids and a synergistic component which gives an antioxidation effect both in vivo and in vitro. This combination has, according to the invention, given surprising advantageous properties in the form very good clinical effects, better functional properties and longer storage life. The inventors have shown that a particularly advantageous effect is obtained using a product that contains oil from marine mammals, preferably the seal, and cold-pressed virgin olive oil, both of these components being produced in a per se known way. The effect obtained may seem to be more pronounced than would be expected if each component were used alone.
Thus, the invention relates to a combination of oils as a supplement to a regular diet, characterised in that it comprises a combination of seal oil and cold-pressed virgin olive oil.
The invention also relates to the use of the combination according to the invention as a component in an oil-in-water or water-in-oil emulsion in foodstuffs.
Furthermore, the invention relates to the use of the combination according to the invention, optionally together with adjuvants, for example, for preparing a composition for counteracting the development of coronary heart disease and thromboses and to suppress psoriasis, rheumatism and other proinflammatory diseases.
Two clinical studies have been conducted on the effect of using a dietary oil according to the invention as a daily supplement for healthy individuals. In the first study there were 28 participants in both the control group and the group that received the dietary oil according to the invention, whilst there were 37 participants in a cod-liver oil (CLO) group. Each person consumed 15 ml oil per day or nothing (the control group) for 12 weeks. Although there was a higher rise in omega-3 fatty acids in the serum of the individuals in the CLO group compared with the group that received the combination of oils according to the invention, the reduction in LPS -induced TNF in whole blood was 24.0% in the group that received the combination of oils according to the invention compared with 5.0% in the CLO group. This shows, as in the previously mentioned study, that the reduction in the amount of inflammatory products in stimulated blood cells is not directly related to the content of omega-3 fatty acids (østerud et al. 1995).
Another study produced the results given in Table 1 :
Table 1. The effect of a dietary supplement of CLO or the combination of oils according to the invention compared with a control (% change compared with values obtained prior to dietary intake)
Table 1 shows a change in some of the most important parameters related to coronary heart disease (CHD). HDL-chol is the beneficial cholesterol and any positive change in this is a good thing. Hypersensitive C-reactive protein (hs-CRP) reflects chronic inflammatory reactions in the body. It has been shown that increased values of between
0 and 5 mmol/1 are a good risk indicator for coronary heart disease, and especially when the proportion of total cholesterol over HDL cholesterol related to hs-CRP increases (Rifai N, Ridker PM "Inflammatory markers and coronary heart disease" Curr Opin Lipidol. 2002; 13: 383-9. Review). Monocyte chemotactic protein-1 (MCP-I) is a very important chemoattractant protein which plays a major role in the development of atherosclerosis in that it mobilises proinflammatory substances at the site of their production. Thus, any dietary supplement which gives a reduction in MCP-I may be highly beneficial. LTB4 and TxB2 (a stable product of TxA2) are proinflammatory products derived from the metabolism of arachidonic acid.
The above study was carried out on respectively 23, 18 and 19 healthy people in the control group, CLO and the group that received the dietary oil of the invention. The samples were taken from fasting volunteers between 08.00 and 10.00 hours immediately prior to the start of the study and at the end after 12 weeks of supplementary ingestion of 15 grams of oil (or nothing = control). The fatty acid composition before and after was determined in serum samples.
The conclusion of the above study is that the combination of oils according to the invention has the potential to increase the beneficial HDL cholesterol, significantly reduce the important marker and the risk factor for coronary heart disease (hs-CRP) and further reduce MCP-I more efficiently than CLO. In addition, the beneficial effect of reducing the proinflammatory products TxA2 and LTB4 is at the same level as for CLO. Overall, the dietary oil according to the invention as a dietary supplement has significantly more anti-inflammatory effects than CLO, and is superior to olive oil, which has also been used alone as a control in several studies of omega-3 fatty acids and fish oils. The effect of the edible oil according to the invention probably occurs through a synergistic combination of omega-3 fatty acids from the marine oil and strong antioxidants present in the virgin olive oil.
Claims
1.
A combination of oils as a supplement to, or a component of, a regular diet, characterised in that it includes seal oil and cold-pressed virgin olive oil.
2.
A combination according to claim 1, characterised in that the combination is in the form of a blend.
3.
A combination according to claim 1, characterised in that the ratio of seal oil to virgin olive oil is from 1:9 to 9:1, preferably 2:8 to 8: 2 , more preferably 3:7 to 7:3, even more preferably 4:6 to 6:4, and most preferably 1:1.
4.
The use of the combination according to claim 1 as an edible oil or as a component of an oil-in- water or water-in-oil emulsion in foodstuffs.
5.
The use of the combination according to claim 1, optionally with adjuvants, for preparing a composition to counteract the development of coronary heart disease and thromboses and to suppress psoriasis, rheumatism and other proinflammatory diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NO2005/000142 WO2006118463A1 (en) | 2005-05-02 | 2005-05-02 | A combination of seal oil and cold-pressed virgin olive oil |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1895861A1 true EP1895861A1 (en) | 2008-03-12 |
Family
ID=37308193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05750010A Withdrawn EP1895861A1 (en) | 2005-05-02 | 2005-05-02 | A combination of seal oil and cold-pressed virgin olive oil |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1895861A1 (en) |
JP (1) | JP2008539720A (en) |
CN (1) | CN101193560A (en) |
CA (1) | CA2607029A1 (en) |
WO (1) | WO2006118463A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2013000036A1 (en) * | 2013-01-29 | 2014-06-25 | Guetari Sami | OMEGA 3 FOOD SUPPLEMENT BASED ON IMPROVED FISH OIL |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB207545A (en) * | 1922-11-23 | 1924-02-07 | Peter Moeller Heverdahl | A method for producing edible products rich in vitamines |
GB9100497D0 (en) * | 1991-01-10 | 1991-02-20 | Unilever Plc | Oil blends |
DK198991D0 (en) * | 1991-12-10 | 1991-12-10 | Simanol A S | FISH PRODUCTS |
PT102509A (en) * | 2000-08-16 | 2002-02-28 | Fundacao Essprit Icarus | PHARMACEUTICAL, COSMETIC AND DERMO-COSMETIC COMPOSITIONS, OF HYGIENE, FOOD AND FODDER, BASED ON FOCUS OIL, AND THEIR USE |
-
2005
- 2005-05-02 WO PCT/NO2005/000142 patent/WO2006118463A1/en active Application Filing
- 2005-05-02 CN CNA2005800496788A patent/CN101193560A/en active Pending
- 2005-05-02 CA CA002607029A patent/CA2607029A1/en not_active Abandoned
- 2005-05-02 JP JP2008509960A patent/JP2008539720A/en active Pending
- 2005-05-02 EP EP05750010A patent/EP1895861A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2006118463A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006118463A1 (en) | 2006-11-09 |
CA2607029A1 (en) | 2006-11-09 |
CN101193560A (en) | 2008-06-04 |
JP2008539720A (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
La Lastra et al. | Mediterrranean diet and health biological importance of olive oil | |
Nevin et al. | Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation | |
Oh et al. | Eggs enriched inω-3 fatty acids and alterations in lipid concentrations in plasma and lipoproteins and in blood pressure | |
Ruiter et al. | The influence of dietary mackerel oil on the condition of organs and on blood lipid composition in the young growing pig | |
Harris et al. | The comparative reductions of the plasma lipids and lipoproteins by dietary polyunsaturated fats: salmon oil versus vegetable oils | |
Jialal et al. | The role of oxidized low density lipoprotein in atherogenesis | |
Calder et al. | Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques | |
AU2009200897B2 (en) | Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides | |
US6277431B1 (en) | Anticholesterolemic edible oil | |
EP2046312A2 (en) | Pharmaceutical and nutraceutical products comprising vitamin k2 | |
Tomé-Carneiro et al. | Olive oil consumption and its repercussions on lipid metabolism | |
Mesembe et al. | The effects of fresh and thermoxidized palm oil diets on some haematological indices in the rat | |
Simopoulos | Omega-3 fatty acids part II: epidemiological aspects of omega-3 fatty acids in disease states | |
EP1370148A1 (en) | Anticholesterolemic edible oil | |
EP2355812A2 (en) | A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis | |
WO2006118463A1 (en) | A combination of seal oil and cold-pressed virgin olive oil | |
World Health Organization | Fats and Oils in Human Nutrition: Report of a Joint Expert Consultation, Rome, 19-26 October 1993 | |
Zommara et al. | Antiatherogenic effect of Tiger nut tubers (Cyperus esculentus L.) supplemented diet in apolipoprotein E knockout mice | |
EP3420822B1 (en) | Combination of oils | |
NO320284B1 (en) | Combination of oils and their use. | |
JPH09308459A (en) | Nutritive composition containing highly unsaturated fatty acid | |
Sanders | The Mediterranean diet: fish and olives, oil on troubled waters | |
Kazeem et al. | Role of fixed oil and fats in human physiology and pathophysiology | |
O'Brien et al. | Biological effects of dietary cholesterol oxidation products | |
KR100891493B1 (en) | Pufferfish liver oil with biofunctional activities and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071130 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20091103 |